Literature DB >> 28872154

Ethnicity and ERG frequency in prostate cancer.

Jason Sedarsky1, Michael Degon1, Shiv Srivastava2, Albert Dobi2.   

Abstract

Emerging observations emphasize a distinct biology of prostate cancer among men of different ethnicities and races, as demonstrated by remarkable differences in the frequency of ERG oncogenic activation, one of the most common and widely studied prostate cancer driver genes. Worldwide assessment of ERG alterations frequencies show consistent trends, with men of European ancestry having the highest rates of alteration and men of African or Asian ancestries having considerably lower alteration rates. However, data must be interpreted cautiously, owing to variations in assay platforms and specimen types, as well as ethnic and geographical classifications. Many opportunities and challenges remain in assessing cancer-associated molecular alterations at a global level, and these need to be addressed in order to realize the true potential of precision medicine for all cancer patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28872154     DOI: 10.1038/nrurol.2017.140

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  118 in total

1.  Mapping genes that predict treatment outcome in admixed populations.

Authors:  T M Baye; R A Wilke
Journal:  Pharmacogenomics J       Date:  2010-10-05       Impact factor: 3.550

2.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

3.  TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.

Authors:  Jun Dong; Li Xiao; Lu Sheng; Jun Xu; Zhong-Quan Sun
Journal:  Asian Pac J Cancer Prev       Date:  2014

4.  Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study.

Authors:  Qi-Peng Sun; Liao-Yuan Li; Zhong Chen; Jun Pang; Wei-Jiao Yang; Xiang-Fu Zhou; Jian-Guang Qiu; Zu-Lan Su; Dan He; Xin Gao
Journal:  J Mol Diagn       Date:  2010-07-08       Impact factor: 5.568

5.  Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos.

Authors:  Eliza M Raymundo; Michele H Diwa; Marie Carmela M Lapitan; Aladin B Plaza; Jesus Emmanuel Sevilleja; Shiv Srivastava; Isabell A Sesterhenn
Journal:  Prostate       Date:  2014-06-09       Impact factor: 4.104

6.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

Review 7.  Genomic Predictors of Outcome in Prostate Cancer.

Authors:  Peter J Boström; Anders S Bjartell; James W F Catto; Scott E Eggener; Hans Lilja; Stacy Loeb; Jack Schalken; Thorsten Schlomm; Matthew R Cooperberg
Journal:  Eur Urol       Date:  2015-04-23       Impact factor: 20.096

8.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Authors:  Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

9.  ERG induces taxane resistance in castration-resistant prostate cancer.

Authors:  Giuseppe Galletti; Alexandre Matov; Himisha Beltran; Jacqueline Fontugne; Juan Miguel Mosquera; Cynthia Cheung; Theresa Y MacDonald; Matthew Sung; Sandra O'Toole; James G Kench; Sung Suk Chae; Dragi Kimovski; Scott T Tagawa; David M Nanus; Mark A Rubin; Lisa G Horvath; Paraskevi Giannakakou; David S Rickman
Journal:  Nat Commun       Date:  2014-11-25       Impact factor: 14.919

10.  Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.

Authors:  Byeong-Joo Noh; Ji-Youn Sung; Youn Wha Kim; Sung-Goo Chang; Yong-Koo Park
Journal:  Oncol Lett       Date:  2016-04-19       Impact factor: 2.967

View more
  9 in total

Review 1.  Race and prostate cancer: genomic landscape.

Authors:  Camilo Arenas-Gallo; Jude Owiredu; Ilon Weinstein; Patrick Lewicki; Spyridon P Basourakos; Randy Vince; Bashir Al Hussein Al Awamlh; Fredrick R Schumacher; Daniel E Spratt; Christopher E Barbieri; Jonathan E Shoag
Journal:  Nat Rev Urol       Date:  2022-08-09       Impact factor: 16.430

Review 2.  Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities.

Authors:  Levent Trabzonlu; Ibrahim Kulac; Qizhi Zheng; Jessica L Hicks; Michael C Haffner; William G Nelson; Karen S Sfanos; Onur Ertunc; Tamara L Lotan; Christopher M Heaphy; Alan K Meeker; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Cold Spring Harb Perspect Med       Date:  2019-04-01       Impact factor: 6.915

3.  Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.

Authors:  Qingyu Xiao; Yidi Sun; Albert Dobi; Shiv Srivastava; Wendy Wang; Sudhir Srivastava; Yuan Ji; Jun Hou; Guo-Ping Zhao; Yixue Li; Hong Li
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

4.  Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer.

Authors:  Indu Kohaar; Qiyuan Li; Yongmei Chen; Lakshmi Ravindranath; Denise Young; Amina Ali; Isabell A Sesterhenn; Inger L Rosner; Jennifer Cullen; Shiv Srivastava; Matthew Freedman; Gyorgy Petrovics
Journal:  Oncotarget       Date:  2020-04-14

5.  Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review.

Authors:  De-Pei Kong; Rui Chen; Chun-Lei Zhang; Wei Zhang; Guang-An Xiao; Fu-Bo Wang; Na Ta; Xu Gao; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2020 Mar-Apr       Impact factor: 3.285

6.  Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes.

Authors:  Indu Kohaar; Xijun Zhang; Shiv Srivastava; Gyorgy Petrovics; Shyh-Han Tan; Darryl Nousome; Kevin Babcock; Lakshmi Ravindranath; Gauthaman Sukumar; Elisa Mcgrath-Martinez; John Rosenberger; Camille Alba; Amina Ali; Denise Young; Yongmei Chen; Jennifer Cullen; Inger L Rosner; Isabell A Sesterhenn; Albert Dobi; Gregory Chesnut; Clesson Turner; Clifton Dalgard; Matthew D Wilkerson; Harvey B Pollard
Journal:  Nat Commun       Date:  2022-03-15       Impact factor: 14.919

7.  Transition zone prostate cancer is associated with better clinical outcomes than peripheral zone cancer.

Authors:  Shun Sato; Takahiro Kimura; Hajime Onuma; Shin Egawa; Hiroyuki Takahashi
Journal:  BJUI Compass       Date:  2020-10-06

Review 8.  Epidemiology and genomics of prostate cancer in Asian men.

Authors:  Yao Zhu; Miao Mo; Yu Wei; Junlong Wu; Jian Pan; Stephen J Freedland; Ying Zheng; Dingwei Ye
Journal:  Nat Rev Urol       Date:  2021-03-10       Impact factor: 14.432

9.  Prostate cancer patients' self-reported participation in research: an examination of racial/ethnic disparities.

Authors:  Nynikka R Palmer; Hala T Borno; Steven E Gregorich; Jennifer Livaudais-Toman; Celia P Kaplan
Journal:  Cancer Causes Control       Date:  2021-06-29       Impact factor: 2.532

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.